Connect with us

Press Releases

Orasis Starts US Phase 3 Studies of Presbyopia Eye Drop

The company is enrolling about 600 participants with presbyopia.

mm

Published

on

(PRESS RELEASE) HERZLIYA, ISRAEL — Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the U.S., evaluating its novel eye drop candidate designed to improve near vision for people with presbyopia.

“We are excited to move into the final stage of clinical development of our corrective eye drop while preparing for pre-commercialization,” said Elad Kedar, CEO of Orasis. “Presbyopia, the inability to focus on near objects, is a progressive, ubiquitous condition that affects almost two billion people above the age of 40 all around the world. Orasis is committed to making near vision clear again for people who live with this condition. Our proprietary eye drop formulation was designed to achieve the optimal balance between efficacy, safety, and comfort. Promising results from our well powered Phase 2b study, along with the recent Series C funding, have paved a promising path for us to advance our product candidate through Phase 3 development and pre-commercialization efforts. We look forward to providing this novel and non-invasive option for presbyopia to eyecare providers and patients.”

The NEAR-1 and NEAR-2 Phase 3 studies are multi-center, double-masked, parallel-group clinical trials in the U.S. enrolling approximately 600 participants with presbyopia to further evaluate the efficacy and safety of Orasis’ eye drop candidate. For more information about the studies, visit NEAR-1 and NEAR-2.

SPONSORED VIDEO

SPONSORED BY VARILUX

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular